Recent advances in the discovery of Src kinase inhibitors

Bibliography

• HUBBARD SR, TILL JH: Protein tyrosine kinase structure and function. Ann. Rev. Biochem. (2000) 69:373–398.
   PubMed Web of Science ®Google Scholar
• WARMUTH M, DAMOISEAUX R, LIU Y, FABBRO D, GRAY N: Src family kinases: potential targets for the treatment of human cancer and leukemia. Curr. Pharm. Des. (2003) 9:2043–2059.
   PubMed Web of Science ®Google Scholar
• SUSA M, TETI A: Tyrosine kinase Src inhibitors: potential therapeutic application. Drugs News Perspect. (2000) 13:169–175.
   PubMed Web of Science ®Google Scholar
• SAWYER T, BOYCE B, DALGARNO D, LULIUCCI J: Src inhibitors: genomics to therapeutics. Expert. Opin. Investig Drugs (2001) 10:1327–1344.
   PubMed Web of Science ®Google Scholar
• THOMAS SM, BRUGGE, JS: Cellular functions regulated by Src family kinases. Ann. Rev. Cell Dev. Biol. (1997) 13:513-609. A comprehensive review of the physiology and substrates of Src and Src-family kinases.
   Google Scholar
• YARDEN Y, ULLRICH A: Growth factor receptor tyrosine kinases. Ann. Rev. Biochem. (1988) 57:443–478.
   PubMed Web of Science ®Google Scholar
• COLLETT MS, ERIKSON RL: Protein kinase activity associated with the avian sarcoma virus Src gene product. Proc. Natl. Acad. Sci. USA (1978) 75:2021–2024.
   PubMed Web of Science ®Google Scholar
• BRUGGE JS, ERIKSON RL: Identification of a transformation-specific antigen induced by avian sarcoma virus. Nature (1977) 269:346–348.
   PubMed Web of Science ®Google Scholar
• BISCARDI JS, TICE DA, PARSONS SJ: c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. (1999) 76:61–119.
   PubMed Web of Science ®Google Scholar
• OWENS DW, MCLEAN GW, WYKE AW et al.: The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. MoL Biol. Cell (2000) 11:51–64.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT CA, MEISLER AI, ECKHART W: Activation of the pp60c-Src protein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. USA (1990) 87: 558–562.
   PubMed Web of Science ®Google Scholar
• MAO W, IRBY R, COPPOLA D et al.: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene (1997) 15:3083–3090.
   PubMed Web of Science ®Google Scholar
• SORIANO P, MONTGOMERY C, GESKE R, BRADLEY A: Targeted disruption of the c-Src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 64:693–702.
   PubMed Web of Science ®Google Scholar
• ELICEIRI BP, PAUL R, SCHWARTZBERG PL, HOOD JD, LENG J, CHERESH DA: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. (1999) 4:915–924.
   PubMed Web of Science ®Google Scholar
• PAUL R, ZHANG ZG, ELICEIRI BP et al.: Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. (2001) 7:222–227.
   PubMed Web of Science ®Google Scholar
• LOWELL CA, BERTON G: Integrin signal transduction in myeloid leukocytes. J. Leukoc. Biol. (1999) 65:313–320.
   PubMedGoogle Scholar
• STRAUS DB, WEISS A: Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell (1992) 70:585–593
   PubMed Web of Science ®Google Scholar
• KAMENS JS, RATNOFSKY SE, HIRST GC: Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. Curr. Opin. Investig Drugs (2001) 2:1213–1219.
   PubMedGoogle Scholar
• MOLINA TJ, KISHIHARA K, SIDEROVSKI DP et al.: Profound block in thymocyte development in mice lacking p561ck. Nature (1992) 357:161–164.
   PubMed Web of Science ®Google Scholar
• IRBY RB, YEATMAN TJ: Role of Src expression and activation in human cancer. Oncogene (2000) 19:5636–5642.
   PubMed Web of Science ®Google Scholar
• BOSCHELLI DH, BOSCHELLI F: Small molecule inhibitors of Src family kinases. Drugs Fut. (2000) 25:717–736.
   Google Scholar
• TALAMONTI MS, ROH MS, CURLEY SA, GALLICK GE: Increase in activity and level of pp60c-Src in progressive stages of human colorectal cancer. J. Clin. Invest. (1993) 91:53–60.
   PubMed Web of Science ®Google Scholar
• LUTZ MP, ESSER IBS, FLOSSMANN-KAST BBM et al.: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. (1998) 243:503–508.
   PubMed Web of Science ®Google Scholar
• LYNCH SA, BRUGGE JS, FROMOWITZ F et al.: Increased expression of the Src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas. Leukemia (1993) 7:1416–1422.
   PubMed Web of Science ®Google Scholar
• AVIZIENYTE E, WYKE AW, JONES RJ et al.: Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling. Nat. Cell Biol. (2002) 4:632–638.
   PubMed Web of Science ®Google Scholar
• WEBER TK, STEELE G, SUMMERHAYES IC: Differential pp60c-Src activity in well and poorly differentiated human colon carcinomas and cell lines./ Clin. Invest. (1992) 90:815–821.
   Google Scholar
• PENA SV, MELHEM MF, MEISLER Al,CARTWRIGHT CA: Elevated c-Yes tyrosine kinase activity in premalignant lesions of the colon. Gasteroenterol (1995) 108:117–124.
   PubMed Web of Science ®Google Scholar
• MUTHUSWAMY SK, MULLER WJ: Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene (1995) 11:1801–1810.
   PubMedGoogle Scholar
• OTTENHOLF-KALFF AE, RIJKSEN G, VAN BEURDEN EA, HENNIPMAN A, MICHELS AA, STAAL GE: Characterization of protein tyrosine kinase from human breast cancer. Cancer Res. (1992) 49:4773–4778.
   Google Scholar
• EGAN C, PANG A, DURDA D, CHENG H-C, WANG JH, FUJITA DJ: Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene (1999) 18:1227–1237.
   PubMed Web of Science ®Google Scholar
• VERBEEK BS, VROOM TM, ADRIAANSEN-SLOT SS et al.: c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis./ Pathol (1996) 180:383–388.
   Google Scholar
• WIENER JR, NAKANO K, KRUZELOCK RP, BUCANA CD, BAST RC JR, GALLICK GE: Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin. Cancer Res. (1999) 5:2164–2170.
   PubMed Web of Science ®Google Scholar
• STALEY CA, PARIKH NU, GALLICK GE: Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Duff (1997) 8:269–274.
   PubMedGoogle Scholar
• ELLIS LM, STALEY CA, LIU Wet al.: Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-Src. J. Biol Chem. (1998) 273:1052-1057. 1201 Expert Opin. Ther Patents (2005) 15(9)
   Google Scholar
• BRUNTON VG, OZANNE BW, PARASKEVA C, FRAME MC: A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene (1997) 14:283–293.
   PubMed Web of Science ®Google Scholar
• FINCHAM VJ, FRAME MC: The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO J. (1998) 17:81–92.
   PubMed Web of Science ®Google Scholar
• VERBEEK BS, VROOM TM, RIJKSEN G: Overexpression of c-Src enhances cell-matrix adhesion and cell migration in PDGF-stimulated NIH3T3 fibroblasts. Exp. Cell Research (1999) 248:531–537.
   PubMedGoogle Scholar
• NAM J-S, INO Y, SAKAMOTO M, HIROHASHI S: Src family kinase inhibitor PP2 restores the E-calherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clinical Cancer Res. (2002) 8:2430–2436.
   PubMedGoogle Scholar
• JANKOWSKI J, COGHILL G, HOPWOOD D, WORMSLEY KG: Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut (1992) 33:1033–1038
   PubMed Web of Science ®Google Scholar
• MAZURENKO NN, KOGAN EA, ZBOROVSKAYA IB, KISSELJOV FL: Expression of pp60c-Src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer (1992) 28:372–377
   PubMed Web of Science ®Google Scholar
• LOWE C, YONEDA T, BOYCE BF, CHEN H, MUNDY GR, SORIANO P: Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Nat. Acad. Sci. USA (1993) 90:4485–4489.
   PubMed Web of Science ®Google Scholar
• BOYCE BF, YONEDA T, LOWE C, SORIANO P, MUNDY GR: Requirement of pp60c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice./ Clin. Invest. (1992) 90:1622–1627.
   Google Scholar
• MARZIA M, SIMS NA, VOIT S et aL: Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. (2000) 151:311–320.
   PubMed Web of Science ®Google Scholar
• KOUSTENI S, BELLIDO T, PLOTKIN LI et aL: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 104:719–730.
   PubMed Web of Science ®Google Scholar
• ABU-AMER Y, ROSS FP, SCHLESINGER P, TONDRAVI MM, TEITELBAUM SL: Substrate recognition by osteoclast precursors induces c-Src/ microtubule association./ Cell Biol. (1997) 137:247–258.
   PubMedGoogle Scholar
• WONG BR, BESSER D, KIM N et al.: TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell (1999) 4:1041–1049.
   PubMed Web of Science ®Google Scholar
• TANAKA S, AMLING M, NEFF Let al.: c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature (1996) 383:528–531.
   Google Scholar
• JESCHKE M, BRANDI M-L, SUSA M: Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1.1 Bone Miner. Res. (1998) 13:1880–1889.
   Google Scholar
• TAKAYANAGI H, JUJI T, MIYAZAKI T et aL: Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. j Clin. Invest. (1999) 104:137–146.
   PubMed Web of Science ®Google Scholar
• MISSBACH M, JESCHKE M, FEYEN J et aL: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone (1999) 24:437–449.
   PubMed Web of Science ®Google Scholar
• YONEDA T, SASAKI A, MUNDY GR: Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treat. (1994) 32:73–84.
   PubMed Web of Science ®Google Scholar
• WETS S, SHINTANI S, WEBER A et al.: Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. (2004) 113:885–894.
   PubMedGoogle Scholar
• BULL HA, BRICKELL PM, DOWD PM: Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Letters (1994) 361:41–44.
   Google Scholar
• KIEFER F, ANHAUSER I, SORIANO P et al.: Endothelial cell transformation by polyomavirus middle T antigen in mice lacking Src-related kinases. Curr. Biol. (1994) 4:100–109.
   PubMed Web of Science ®Google Scholar
• YU XM, SALTER MW: Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Proc. Nat. Acad. Sci. USA (1999) 96:7697–7704.
   PubMedGoogle Scholar
• GUO W, ZOU S, GUAN Yet al.: Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. j Neuro. (2002) 22:6208–6217.
   Google Scholar
• KLEIN NP, BOUCHARD MJ, WANG L-H, KOBARG C, SCHNEIDER RJ: Src kinases involved in hepatitis B virus replication. EMBO J.(1999) 18:5019–5027
   PubMedGoogle Scholar
• KLEIN NP, SCHNEIDER RJ: Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. MoL Cell Biol. (1997) 17:6427–6436.
   PubMed Web of Science ®Google Scholar
• PALACIOS EH, WEISS A: Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene (2004) 23:7990–8000.
   PubMed Web of Science ®Google Scholar
• WAEGELL W, BABINEAU M, HART M et al.: A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection. Transplant. Proceed. (2002) 34:1411–1417.
   PubMed Web of Science ®Google Scholar
• TAYLOR SS, RADZIO-ANDZELM E: Three protein kinase structures define a common motif. Structure (1994) 2:345–355.
   PubMedGoogle Scholar
• PARANG K, COLE Pk Bisubstrate inhibitors of protein kinases. PharmacoL Ther. (2002) 93:145-157. A comprehensive review discussing failures and successes in developing bisubstrate inhibitors of protein kinases.
   Google Scholar
• YOON MY, COOK PF: Chemical mechanism of the adenosine cyclic 3',5'-monophosphate dependent protein kinase from pH studies. Biochemistry (1987) 26:4118–4125.
   PubMedGoogle Scholar
• SCHULZE-GAHMEN U, BRANDSEN J, JONES HD: Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins (1995) 22:378–391.
   PubMed Web of Science ®Google Scholar
• XU W, DOSHI A, LEI M, ECK MJ, HARRISON SC: Crystal structures of c-Src reveal features of its autoinhibitory mechanism. MoL Cell (1999) 3:629–638.
   PubMed Web of Science ®Google Scholar
• SAWYER TK: Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers (1998) 47:243–261.
   Google Scholar
• SONGYANG Z, SHOELSON SE, CHAUDHURI M et aL: 5H2 domains recognize specific phosphopeptide sequences. Cell (1993) 72:767–778.
   PubMed Web of Science ®Google Scholar
• SADOWSKI I, STONE JC, PAWSON T: A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. MoL CelL BioL (1986) 6:4396–4408.
   PubMed Web of Science ®Google Scholar
• CANTLEY LC, AUGER KR, CARPENTER Get al.: Oncogenes and signal transduction. Cell (1991) 64:281–302.
   Google Scholar
• FUKUI Y, HANAFUSA H: Requirement of phosphatidylinosito1-3 kinase modification for its association with p60Src. Mol. Cell. Biol. (1991) 11:1972–1979.
   PubMedGoogle Scholar
• SCHALLER MD, HILDERBRAND JD, SHANNON JD, FOX JW VINES RR, PARSONS JT: Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2 dependent binding of pp60Src. MoL Cell. Biol. (1994) 14:1680–1688.
   PubMed Web of Science ®Google Scholar
• TAYLOR SJ, SHALLOWAY D: An RNA-binding protein associated with Src through its 5H2 and 5H3 domains in mitosis. Nature (1994) 368:867–871.
   PubMed Web of Science ®Google Scholar
• PETCH LA, BOCKHOLT SM, BOUTON A, PARSONS JT, BURRIDGE K: Adhesion-induced tyrosine phosphorylation of the p130 Src substrate. J. Cell. Sci. (1995) 108:1371–1379.
   PubMed Web of Science ®Google Scholar
• ERPEL T, COURTNEIDGE SA: Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol. (1995) 7:176–182.
   PubMed Web of Science ®Google Scholar
• THOMAS JW, ELLIS B, BOERNER RJ: 5H2- and 5H3-mediated interactions between focal adhesion kinase and Src. J. Biol. Chem. (1998) 273:577–583.
   PubMed Web of Science ®Google Scholar
• ALEXANDROPOULOS K, BALTIMORE D: Coordinate activation of c-Src by 5H3- and 5H2 binding sites on a novel, p130CAS-related protein, Sin. Genes Dev. (1996) 10:1341–1355.
   PubMed Web of Science ®Google Scholar
• XU W, HARRISON SC, ECK MJ: Three-dimensional structure of the tyrosine kinase c-Src. Nature (1997) 385:595–602.
   PubMed Web of Science ®Google Scholar
• SICHERI F, KURIYAN J: Structures of Src-family tyrosine kinases. Curr. Opin. Struct. Biol. (1997) 7:777–785.
   PubMed Web of Science ®Google Scholar
• SICHERI F, MOAREFI I, KURIYAN J: Crystal structure of the Src family tyrosine kinase Hck. Nature (1997) 385:602–609.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, SICHERI F, PICO A. GAZIT A, LEVITZKI A, KURIYAN J: Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. MoL Cell (1999) 3:639–648.
   Google Scholar
• ZHU X, KIM JL, NEWCOMB JR et al: Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure Fold Des. (1999) 7:651–661.
   Google Scholar
• YAMAGUCHI H, HENDRICKSON Wk Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature (1996) 384:484–489.
   PubMed Web of Science ®Google Scholar
• MOAREFI H, LAFEVRE-BERNT M, SICHERI F et al.: Activation of the Src-family tyrosine kinase Hck by 5H3 domain displacement. Nature (1997) 385:650–653.
   PubMed Web of Science ®Google Scholar
• HUBBARD SR: Structural analysis of receptor tyrosine kinases. Frog. Biophys. Mol Biol (1999) 71:343–358.
   PubMed Web of Science ®Google Scholar
• MANDINE E, JEAN-BAPTISTE V VAYSSIERE Bet al.: High-affinity Src-5H2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system. Biochem. Biophys. Res. Commun. (2002) 298:185–192.
   Google Scholar
• LIU X, BRODEUR SR, GISH G et al: Regulation of c-Src tyrosine kinase activity by the Src 5H2 domain. Oncogene (1993) 8:1119–1126.
   PubMed Web of Science ®Google Scholar
• ALONSO G, KOEGL M, MAZURENKO N, COURTNEIDGE SA: Sequence requirements for binding of Src family tyrosine kinases to activated growth factors. J. Biol Chem. (1995) 270:9840–9848.
   PubMed Web of Science ®Google Scholar
• BOERNER RJ, KASSEL DB, BARKER SC, ELLIS B, DELACY P, KNIGHT WB: Correlation of the phosphorylation states of pp60c-s" with tyrosine kinase activity: the intramolecular pY530-5H2 complex retains significant activity if Y419 is phosphorylated. Biochem. (1996) 35:9519–9525.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ: Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol (2003) 40:50–58.
   PubMed Web of Science ®Google Scholar
• WAKELING AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol (2002) 2:382–387.
   PubMedGoogle Scholar
• MARX SO, MARKS AR: Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation (2001) 104:852–855.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al: (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl. J. Med. 344:783–792.
   PubMed Web of Science ®Google Scholar
• MITCHELL P: Erbitux diagnostic latest adjunct to cancer therapy. Nat. Biotechnology (2004) 22:363–364.
   PubMedGoogle Scholar
• ROSKOSKI RJR: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. (2004) 319:1–11.
   PubMedGoogle Scholar
• FERRARA N, HILLAN KJ, GERBER H-P, NOVOTONY W: Discover and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Dis. (2004) 3:391–400.
   PubMed Web of Science ®Google Scholar
• TSYGANKOV AY, SHORE SK: Src: regulation, role in human carcinogenesis and pharmacological inhibitors. Curr. Pharm. Des. (2004) 10:1745-1756. A current comprehensive review of the design of Src tyrosine kinases
   Google Scholar
• SCHENONE S, BRUNO 0, RANISE A: New pyrazolo13,4-ffipyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg. Med. Chem. Lett. (2004) 14:2511–2517.
   PubMed Web of Science ®Google Scholar
• BOSCHELLI DH, WANG YD, YE F et al.: Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. (2001) 44:822–833.
   PubMed Web of Science ®Google Scholar
• PARANG K, SUN G: Design strategies for protein kinases inhibitors. Curr. Opin. Drug Discov. Devel (2004) 7:630–638.
   PubMedGoogle Scholar
• FORCE T, KUIDA K, PARANG K, KYRIAKIS JM: Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation (2004) 109:1196–1205.
   PubMedGoogle Scholar
• MACHIDA K, MAYER BJ: The 5H2 domain: versatile signaling module and pharmaceutical target. Biochimic. Biophys. Acta (2005) 1747:1-25. A comprehensive review of the SH2 domain and designing Src SH2 domain inhibitors.
   Google Scholar
• VU CB: Recent advances in the design and synthesis of 5H2 inhibitors of Src, Grb2 and ZAP-70. Curr. Med. Chem. (2000) 7:1081–1100.
   PubMed Web of Science ®Google Scholar
• VU CB, CORPUZ EG, PRADEEPAN SG, VIOLETTE S, BARTLETT C, SAWYER TK: Nonpeptidic 5H2 inhibitors of the tyrosine kinase ZAP-70. Bioorg. Med. Chem. Lett. (1999) 9:3009–3014.
   PubMedGoogle Scholar
• NAM NH, PITTS R, SUN Get al.: Design of tetrapeptide ligands as inhibitors of the Src 5H2 domain. Bioorg Med. Chem. (2004) 12:779–787.
   Google Scholar
• NAM NH, YE G, SUN G, PARANG K: Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src 5H2 domain binding. J. Med. Chem. (2004) 47:3131–3141.
   PubMedGoogle Scholar
• MULLER G: Peptidomimetics SH2 domain antagonists for targeting signal transduction. Topics Curr Chem. (2000) 211:17–59.
   Web of Science ®Google Scholar
• VU CB, CORPUZ EG, MERRY TJ et al: Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J. Med. Chem. (1999) 42:4088–4098.
   PubMed Web of Science ®Google Scholar
• CODY WL, UN Z, PANEK RL, ROSE DW, RUBIN JR: Progress in the development of inhibitors of 5H2 domains. Curr. Pharm. Des. (2000) 6:59–98.
   PubMed Web of Science ®Google Scholar
• PARK J, FU H, PEI D: Peptidyl aldehydes as reversible covalent inhibitors of Src homology 2 domains. Biochem. (2003) 42:5159–5167.
   PubMedGoogle Scholar
• MARSEIGNE I, ROQUES BP: Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues./ Org. Chem. (1988) 53:3621–3624.
   Google Scholar
• BURKE TR JR, RUSS P, LIM B: Preparation of 4- [Itis(tert-butoxy)phosphorylmethy1]-N-(fluoren-9-ylmethoxycarbony1)-DL-phenylalanine. A hydrolytically stable analog of 0-phosphotyrosine potentially suitable for peptide synthesis. Synthesis (1991) 11:1019–1020.
   Google Scholar
• SHOELSON SE, CHATTERJEE S, CHAUDHURI M, BURKE TR JR: Solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogs with Na-Fmoc-(0, 0-di- tert-butyl)phosphono-p-methylphenylalanine. Tet. Lett. (1991) 32:6061–6064.
   Google Scholar
• SMYTH MS, FORD H JR, BURKE TR JR: A general method for the preparation of benzylic a,a-difluorophosphonic acids; non-hydrolyzable mimetics of phosphotyrosine. Tet. Lett. (1992) 33:4137–4140.
   Web of Science ®Google Scholar
• BURKE TR JR, SMYTH MS, NOMIZU M, OTAKA A, ROLLER PR: Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of 0-phosphotyrosine. J. Org. Chem. (1993) 58:1336–1340.
   Google Scholar
• BURKE TR JR, SMYTH MS, OTAKA A et al.: Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant 5H2 domain inhibitors. Biochem. (1994) 33:6490–6494.
   PubMedGoogle Scholar
• YAO ZJ, KING CR, GAO T et al.: Potent inhibition of Grb2 5H2 domain binding by non-phosphate-containing ligands. J. Med. Chem. (1999) 42:25–35.
   PubMed Web of Science ®Google Scholar
• SUNDARAMOORTHI R, KAWAHATA N, YANG MG et al: Structure-based design of novel nonpeptide inhibitors of the Src 5H2 domain: phosphotyrosine mimetics exploiting multifunctional group replacement chemistry. Biopo/ymers (2003) 71:717–729.
   PubMedGoogle Scholar
• SHAHRIPOUR A, PLUMMER MS, LUNNEY EA et al.: Novel phosphotyrosine mimetics in the design of peptide ligands for pp60(Src) 5H2 domain. Bioorg. Med. Chem. Let. (1996) 6:1209–1214.
   Google Scholar
• YE B, AKAMATSU M, SHOELSON SE et al: L-0-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides./ Med. Chem. (1995) 38:4270–4275.
   PubMedGoogle Scholar
• BURKE TR, YAO ZJ, ZHAO H et al.: Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides. Tetrahedron (1998) 54:9981–9994.
   Google Scholar
• GAO Y, BURKE TR: Stereoselective preparation of L-4-(2'-malonyl)phenylalanine suitably protected for Fmoc-based synthesis of potent signal transduction inhibitory ligands. Syn/ett (2000) 1:134–136.
   Google Scholar
• GAO Y, LUO J, YAO ZJ et al.: Inhibition of Grb2 5H2 domain binding by non-phosphate-containing ligands. 2. 4-(2-malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J. Med. Chem. (2000) 43:911–920.
   Google Scholar
• GILMER T, RODRIGUEZ M, JORDAN S et al.: Peptide inhibitors of Src 5H3-5H2-phosphoprotein interactions. J. Biol. Chem. (1994) 269:31711–31719.
   PubMedGoogle Scholar
• TONG L, WARREN TC, LUKAS S et al: Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in 5H2 domain binding. J. Biol. Chem. (1998) 273:20238–20242.
   PubMed Web of Science ®Google Scholar
• NAM NH, LEES, YE G, SUN G, PARANG K: ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg. Med. Chem. (2004) 12:5753–5766.
   PubMedGoogle Scholar
• METCALF CA III, VAN SCHRAVENDIJK MR, DALGARNO DC, SAWYER TK: Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr. Pharm. Des. (2002) 8:2049–2075.
   PubMed Web of Science ®Google Scholar
• SUNDARAMOORTHI R, SHAKESPEARE WC, KEENAN TP et al.: Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues. Bioorg. Med. Chem. Lett. (2003) 13:3063–3066.
   PubMed Web of Science ®Google Scholar
• SAWYER TK, BOHACEK RS, EYERMANN CJ et al: Src homology-2 inhibitors: peptidomimetic and nonpeptide. Minirev. Med. Chem. (2002) 2:475–489.
   Google Scholar
• SHAKESPEARE W, YANG M, BOHACEK R et al: Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl Acad. Sci. USA (2000) 97:9373–9378.
   PubMed Web of Science ®Google Scholar
• DALGARNO DC, BOTFILED MC, RICKLES RJ: 5H3 domains and drug design: ligands, structure, and biological function. Biopolymers (1997) 43:383–400.
   PubMed Web of Science ®Google Scholar
• NGUYEN JT, TURCK CW, COHEN FE, ZUCKERMANN RN, LIM Wk Exploiting the basis of proline recognition by 5H3 and WW domains: design of N-substituted inhibitors. Science (1998) 282:2088–2092.
   PubMed Web of Science ®Google Scholar
• YU H, CHEN JK, FENG S, DALGARNO DC, BRAUER AW, SCHREIBER SL: Structural basis for the binding of proline-rich peptides to 5H3 domains. Cell (1994) 76:933–945.
   PubMed Web of Science ®Google Scholar
• KOHDA D, HATANAKA H, ODAKA M et al: Solution structure of the 5H3 domain of phospholipase C.-y. Cell (1993) 72:953–960.
   PubMedGoogle Scholar
• LAWRENCE DS, NIU J: Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther. (1998) 77:81–114.
   PubMed Web of Science ®Google Scholar
• STOUT TJ, FOSTER PG, MATTHEWS DJ: High-throughput structural biology in drug discovery: protein kinases. Cuff. Pharm. Des. (2004) 10:1069–1082.
   PubMed Web of Science ®Google Scholar
• WU SY, MCNAE I, KONTOPIDIS G et al: (2003). Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure11:399–410.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: Protein kinase inhibitors as therapeutic modality. Acc. Chem. Res. (2003) 36:462–469.
   PubMed Web of Science ®Google Scholar
• HUSE M, KURIYAN J: The conformational plasticity of protein kinases. Cell (2002) 109:275–282.
   PubMed Web of Science ®Google Scholar
• SHOWALTER HD, KRAKER AJ: Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases. PharmacoL Ther. (1997) 76:55–71.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, LYDON NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J CAn. Invest. (2000) 105:3–7.
   PubMed Web of Science ®Google Scholar
• WAKELING AE, GUY SP, WOODBURN JR et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. (2002) 62:5749–5754.
   PubMed Web of Science ®Google Scholar
• TOPALY J, ZELLER WJ, FRUEHAUF S: Synergistic activity of the new ABL-specific tyrosine kinase inhibitor 5TI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia (2001) 15:342–347.
   PubMed Web of Science ®Google Scholar
• THIESING JT, OHNO-JONES S, KOLIBABA KS, DRUKER BJ: Efficacy of 5TI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood (2000) 96:3195–3199.
   PubMed Web of Science ®Google Scholar
• TRAXLER P: Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin. Ther Patents (2003) 7:215–234.
   Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al: Clinical resistance to STI-1571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science (2001) 293:876–880.
   Google Scholar
• AZAM M, LATEK RR, DALEY GO: Mechanisms of autoinhibition and STI-571/ Imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 112:831–843.
   PubMed Web of Science ®Google Scholar
• SCHULTZ J: Apparent adverse drug reactions prompt concern about Iressa. J. Natl. Cancer. Inst. (2003) 95:577–579.
   PubMedGoogle Scholar
• BUCHDUNGER E, CIOFFI CL, LAWN et al: Abl protein-tyrosine kinase inhibitor 5T1571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol Exp Ther. (2000) 295:139–145.
   PubMed Web of Science ®Google Scholar
• OKUDA K, WEISBERG E, GILLILAND DG, GRIFFIN JD: ARG tyrosine kinase activity is inhibited by 5T1571. Blood (2001) 97:2440–2448.
   PubMed Web of Science ®Google Scholar
• ROUMIANTSEV S, SHAH NP, GORRE ME et aL: Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl Acad. ScLUSA (2000) 99:10700–10705.
   Google Scholar
• GUMIREDDY K, BAKER SJ, COSENZA SC et aL: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl Acad. Sci.USA (2005) 102:1992–1997.
   PubMed Web of Science ®Google Scholar
• TOLEDO LM, LYDON NB, ELBAUM D: The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. (1999) 6:775–805.
   PubMed Web of Science ®Google Scholar
• TRAXLER P: Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opin. Ther. Patents (1998) 8:1599–1625.
   Web of Science ®Google Scholar
• COHEN P: Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. (2002) 1:309–315.
   Google Scholar
• ••An excellent review of protein kinaseinhibitors in clinical trials.
   Google Scholar
• HAMBY JM, CONNOLLY CJC, SCHROEDER MC et al: Structure-activity relationships for a novel series of pyrido12,3-d1pyrimidine tyrosine kinase inhibitors. J. Med. Chem. (1997) 40:2296–2303.
   PubMedGoogle Scholar
• KLUTCHKO SR, HAMBY JM, BOSCHELLI DH et al.: 2-Substituted aminopyrido12,3-d1pyrimidine-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. (1998) 41:3276–3292.
   Google Scholar
• CHEN P, NORRIS D, IWANOWICZ EJ et al.: Discovery and initial SAP. of imidazoquinoxalines as inhibitors of the Src-family kinase p561-ck. Bioorg. Med. Chem. Let. (2002) 12:1361–1364.
   Google Scholar
• CHEN P, NORRIS D, IWANOWICZ EJ et al.: Synthesis and SAP. of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency. Bioorg. Med. Chem. Let. (2002) 12:3153–3156.
   Google Scholar
• YONEDA T, LOWE C, LEE C-H et al: Herbimycin A, a pp60c-Src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J. Clin. Invest. (1993) 91:2791–2795
   PubMed Web of Science ®Google Scholar
• HALL TJ, SCHAERIBLIN M, MISSBACH M: Evidence that c-Src is involved in the process of osteoclast bone resorption. Biochem. Biophys. Res. Comm. (1994) 199:1237–1244.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, HORI M, TAKEUCHI T, UMEZAWA H: Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60Src in rat kidney cells infected with Rous sarcoma virus. MoL Cell. Biol. (1986) 6:2198–2206.
   PubMed Web of Science ®Google Scholar
• MURAKAMI Y, MIZUNO S, HORT M, UEHARA Y: Reversal of transformed phenotypes by herbimycin A in Src oncogene expressed rat fibroblasts. Cancer Res. (1988) 48:1587–1590.
   PubMed Web of Science ®Google Scholar
• KWON HJ, YOSHIDA M, FUKUI Y, HORINOUCHI S, BEPPU T: Potent and specific inhibition of p60 v-Src protein kinase both in vivo and in vitro by radicicol. Cancer Res. (1992) 52:6926–6930.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, FUKUZAWA H: Use and selectivity of herbimycin A as inhibitor of protein tyrosine kinases. Methods Enzymol (1991) 201:370–379.
   PubMed Web of Science ®Google Scholar
• LAMERS MBAC, ANSTON AA, HUBBARD RE, SCOTT RK, WILLIAMS DH: Structure of C-terminal Src kinase (CSK) in complex with staurosporine. Mokr. Bia (1999) 28:713–725.
   Google Scholar
• SLATE DL, LEE RH, RODRIGUEZ J, CREWS P: The marine nature product, halistanol trisulfate, inhibits pp60v-src protein tyrosine kinase activity. Biochem. Biophys. Res. Comm. (1994) 203:260–264.
   PubMed Web of Science ®Google Scholar
• FALTYNEK CR, SCHROEDER J, MAUVAIS P et al.: Damnacanthal is a highly potent, selective inhibitor of p561ck tyrosine kinase activity. Biochemistry (1995) 34:12404–12410.
   PubMed Web of Science ®Google Scholar
• AKIYAMA T, ISHIDA J, NAKAGAWA S et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. (1987) 262:5592–5595.
   PubMed Web of Science ®Google Scholar
• NISHIO K, MIURA K, OHIRA T, HEIKO Y, SAIJO N: Genistein, a tyrosine kinase inhibitor, decreased the affinity of p561ck to 0-chain of interleukin-2 receptor in human natural killer (NK)-rich cells and decreased NK-mediated cytotoxicity. Proc. Soc. Exp. Biol. Med. (1994) 207:227–233.
   PubMedGoogle Scholar
• GAMES R, WILDER L, MISSBACH M et al.: NVP-AAK980, a novel 6-phenylamino-alkylamino-purine derivative, potently inhibits the tyrosine kinase Src and bone resorption. J. Bone Miner. Res. (1999)14:S487 .
   PubMedGoogle Scholar
• BAIN J, MCLAUCHLAN H, ELLIOTT M, COHEN P: The specificities of protein kinase inhibitors: an update. Biochem. J. (2003) 371:199–204.
   PubMed Web of Science ®Google Scholar
• HANKE JH, GARDNER: JP, DOW RL et al.: Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and Fyn T-dependent T cell activation.J Biol Chem. (1996) 271:695–701.
   Google Scholar
• WALTENBERGER J, UECKER A, KROLL J et al.: A dual inhibitor of platelet-derived growth factor 0-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells: a novel candidate for prevention of vascular remodeling. Circa. Res. (1999) 5:12–22.
   Google Scholar
• BISHOP AC, SHOKAT KM: Acquisition of inhibitor-sensitive protein kinases through protein design. PharmcoL Ther. (1999) 82:337–346.
   PubMed Web of Science ®Google Scholar
• KARNI R, MIZRACHI S, REISS-SKLAN E, GAZIT A, LIVNAH 0, LEVITZKI A: The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBs Lett. (2003) 537:47–52.
   PubMedGoogle Scholar
• MCRAE BL, WALLACE C, DIXON KF et al.: Suppression of CD4* T cell activation by a novel inhibitor of Src family kinases. Int. Immunopharmacol (2005) 5:667–677.
   PubMed Web of Science ®Google Scholar
• BORHANI DW, CALDERWOOD DJ, FRIEDMAN MM et al: A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg. Med. Chem. Lett. (2004) 14:2613–2616.
   PubMed Web of Science ®Google Scholar
• WAEGELL W, BABINEAU M, HART M et al.: A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection. Transplant. Proc. (2002) 34:1411–1417.
   PubMed Web of Science ®Google Scholar
• KNEISSEL M, GAMSE R, MISSBACK M et al: Tyrosine kinase Src inhibitor CGP 76030 suppresses rapid bone loss induced by retinoic acid in rats. Cala": Tissue Int. (1999) 64:(Supp1.1):575.
   Google Scholar
• KRAKER AJ, HARTL BG, AIVIAR AM, BARVIAN MR, SHOWALTER HDH, MOORE CW: Biochemical and cellular effects of c-Src kinase-selective pyrido [2,3-pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol (2000) 60:885–898.
   PubMed Web of Science ®Google Scholar
• MOASSER MM, SRETHAPAKDI M, SACHAR KS, KRAKER AJ, ROSEN N: Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. (1999) 59:6145–6152.
   PubMed Web of Science ®Google Scholar
• PANEK RI,, LU GH, KLUTCHKO SR et al.: In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor J. Pharmacol Exp. Ther. (1997) 283:1433–1444.
   Google Scholar
• ZIMMERMAN J, BUCHDUNCER E, METT H, MEYER T, LYDON NB: Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. (1997) 7:187–192.
   Web of Science ®Google Scholar
• BOSCHELLI DH, YE F, WANG YD et al.: Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. (2001) 44:3965–3977.
   PubMed Web of Science ®Google Scholar
• WANG YD, MILLER K, BOSCHELLI DH et al: Inhibitors of Src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazoline. Bioorg. Med. Chem. Lett. (2000) 10:2477–2480.
   PubMed Web of Science ®Google Scholar
• MYERS MR, SETZER NN, PADA AP et al: The preparation and SAP. of 4-(aniline), (4-phenoxy), and 4-(thiophenoxy)-quinazoline: inhibitors of p561ck and EGF-R tyrosine kinase activity. Bioorg. Med. Chem. Lett. (1997) 7:417–420.
   Google Scholar
• GOLAS JM, ARNDT K, ETIENNE C et al: SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. (2003) 63:375–381.
   PubMed Web of Science ®Google Scholar
• SNOW RJ, CARDOZO MG, MORWICK TM et al: Discovery of 2-phenylamino-imidazoisoquinolin-9-ones: a new class of inhibitors of Lck kinase. J. Med. Chem. (2002) 45:3394–3405.
   PubMed Web of Science ®Google Scholar
• GOLDBERG DR, BUTZ T, CARDOZO MG et al: Optimization of 2-phenylaminoimidazo [4, 5-h] isoquinolin-9-ones: orally active inhibitors of lck kinase. J. Med. Chem. (2003) 46:1337–1349.
   PubMed Web of Science ®Google Scholar
• MOFFAT DF, ALLEN RA, RAPECKI SE et al: 4-Thiophenoxy-N-(3,4,5-trialkoxyphenyl)pyrimidine-2-amines as potent and selective inhibitors of the T-cell tyrosine kinase p561ck. Cuff. Med. Chem. (2004) 11:747–753.
   PubMedGoogle Scholar
• BLAKE RA, BROOME MA, LIU X et al: 5U6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. MoL Cell Biol. (2000) 20:9018–9027.
   PubMed Web of Science ®Google Scholar
• HUANG CK, WU FY, Al YX: Polyhydroxylated 3-(N-phenyl) carbamoy1-2-iminochromene derivatives as potent inhibitors of tyrosine kinase p60c. Bioorg. Med. Chem. Lett. (1995) 5:2423–2428.
   Web of Science ®Google Scholar
• BRUNS CJ, SOLORZANO CC, HARBISON MT et al: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. (2000) 60:2926–2935.
   PubMed Web of Science ®Google Scholar
• MOASSER MM, SRETHAPAKDI M, SACHAR KS, KRAKER AJ, ROSEN N: Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. (1999) 59:6145–6152.
   PubMed Web of Science ®Google Scholar
• WITYAK J, DAS J, MOQUIN RV SHEN Z et al: Discovery and initial SAP. of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). Bioorg. Med. Chem. Lett. (2003) 13:4007–4010.
   PubMedGoogle Scholar
• WIJETUNGE S, HUGHES AD: pp60c-sr' Increases voltage-operated calcium channel currents in vascular smooth muscle cells. Biochem. Biophys. Res. Comm. (1995) 217:1039–1044.
   PubMed Web of Science ®Google Scholar
• WIJETUNGE S, LYMN JS, HUGHES AD: Effect of inhibition of tyrosine phosphatases on voltage-operated calcium channel currents in rabbit isolated ear artery cells. British J. Pharmacol (1998) 124:307–316.
   PubMedGoogle Scholar
• LOU Q, LEFTWICH ME, MCKAY RT, SALMON SE, RYCHETSKY L, LAM KS: Potent pseudosubstrate-based peptide inhibitors for p60c-src protein tyrosine kinase. Cancer Res. (1997) 57:1877–1881.
   PubMedGoogle Scholar
• LAM KS, WI] J, LOU Q: Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases. Int. J. Pept. Protein Res. (1995) 45:587–592.
   PubMedGoogle Scholar
• KAMATH JR, LIU R, ENSTROM AM, LOU Q, LAM, KS: Development and characterization of potent and specific peptide inhibitors of p60c protein tyrosine kinase using pseudosubstrate-based inhibitor design approach. J. Peptide Res. (2003) 62:260–268.
   PubMedGoogle Scholar
• TANOUE T, NISHIDA E: Docking interactions in the mitogen-activated protein kinase cascades. Pharmacol Ther. (2002) 93:193–202.
   PubMed Web of Science ®Google Scholar
• HO DT, BARDWELL AJ, ABDOLLAHI M, BARDWELL L: A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J. Biol. Chem. (2003) 278:32662–32672.
   PubMed Web of Science ®Google Scholar
• LEE S, LIN X, NAM NH, PARANG K, SUN G: Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc. Natl Acad. Sci. USA. (2003) 100:14707–14712.
   PubMed Web of Science ®Google Scholar
• •This first study indicating the presence of a substrate-docking site for Csk.
   Google Scholar
• PARANG K, TILL JH, ABLOOGLU AJ, KOHANSKI RA, HUBBARD SR, COLE PA: Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol. (2001) 8:37–41.
   PubMedGoogle Scholar
• •The first bi-substrate inhibitor for the insulin receptor kinase is discussed.
   Google Scholar
• HINES AC, PARANG K, KOHANSKI RA, HUBBARD SR, COLE PA: Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: molecular yardsticks for analyzing catalytic mechanism and inhibitor design. Bioorg. Chem. (2005) 33:285-297. Patents
   Google Scholar